Fig. 3: Long-term safety of RIDE in vivo. | Nature Nanotechnology

Fig. 3: Long-term safety of RIDE in vivo.

From: Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy

Fig. 3

a, Flowchart for the long-term (7 months) effects of RIDE. b, OCT was used to evaluate RIDE-induced damage in each group. The dot box area was enlarged and placed on the right side. ONL, outer nuclear layer; ELM, external limiting membrane; RPE, retinal pigment epithelium. n = 3 mice. Scale bars, 200 μm (left) and 100 μm (right). c, Representative trace analysis of a- and b-waves in the presence of a scotopic-adapted 3.0 Hz stimulus. d,e, Quantitative analysis of a-wave (d) and b-wave (e) in both the PBS and RIDE groups (n = 7 mice). Data and error bars represent mean ± s.e.m. Two-way ANOVA.

Source data

Back to article page